Safety of monoclonal antibodies for the treatment of multiple sclerosis

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

(2016) Peter Alping et al.   ANNALS OF NEUROLOGY

ALAIN01—Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential

(2016) Tobias Ruck et al.   BMC Neurology

Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases

(2016) Rosy N’gbo N’gbo Ikazabo et al.   CLINICAL THERAPEUTICS

Extended interval dosing of natalizumab in multiple sclerosis

(2016) L Zhovtis Ryerson et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Multiple sclerosis prevalence in the United States commercially insured population

(2016) Piyameth Dilokthornsakul et al.   NEUROLOGY

Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab for Relapsing-Remitting Multiple Sclerosis

(2016) Horst Penkert et al.   JAMA Neurology

Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis

(2015) Pietro Iaffaldano et al.   BRAIN

Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases

(2015) Daniela Rau et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Body weight-based natalizumab treatment in adult patients with multiple sclerosis

(2015) M. Tanaka et al.   JOURNAL OF NEUROLOGY

Switching from natalizumab to fingolimod

(2015) Ludwig Kappos et al.   NEUROLOGY

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2015) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort

(2015) Dalia L. Rotstein et al.   JAMA Neurology

Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use

(2015) Eva Havrdova et al.   Therapeutic Advances in Neurological Disorders

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

(2014) Tatiana Plavina et al.   ANNALS OF NEUROLOGY

The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease

(2014) Helena Marco et al.   BMC MUSCULOSKELETAL DISORDERS

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

(2014) Ludwig Kappos et al.   LANCET NEUROLOGY

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

(2014) Gavin Giovannoni et al.   LANCET NEUROLOGY

Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study

(2014) Neda Ebrahimi et al.   Multiple Sclerosis Journal

Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double-blind placebo-controlled study

(2014) Anat Achiron et al.   Multiple Sclerosis Journal

MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study

(2014) R. J. Fox et al.   NEUROLOGY

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study

(2014) P. S. Sorensen et al.   NEUROLOGY

Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity

(2014) P. Browne et al.   NEUROLOGY

Natalizumab Use During the Third Trimester of Pregnancy

(2014) Aiden Haghikia et al.   JAMA Neurology

Central Nervous System Herpes Simplex and Varicella Zoster Virus Infections in Natalizumab-Treated Patients

(2013) A. J. Fine et al.   CLINICAL INFECTIOUS DISEASES

Central nervous system lymphoma associated with natalizumab

(2013) Angelika Na et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

(2013) Ralf Gold et al.   LANCET

Emerging injectable therapies for multiple sclerosis

(2013) Jiwon Oh et al.   LANCET NEUROLOGY

PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section

(2013) J. R. Berger et al.   NEUROLOGY

Natalizumab-associated complication? First case of peripheral T cell lymphoma

(2012) Jeffrey Schowinsky et al.   ACTA NEUROPATHOLOGICA

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis

(2012) Luigi ME Grimaldi et al.   Multiple Sclerosis Journal

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis

(2011) David B. Clifford   ARCHIVES OF NEUROLOGY

A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis

(2011) A. Cuker et al.   BLOOD

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

(2011) Ludwig Kappos et al.   LANCET

Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

(2011) Alasdair J Coles et al.   LANCET NEUROLOGY

BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis

(2011) M. Bukhari et al.   RHEUMATOLOGY

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

(2011) Hans-Peter Tony et al.   ARTHRITIS RESEARCH & THERAPY

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma

(2010) F. Morschhauser et al.   ANNALS OF ONCOLOGY

Pregnancy outcomes after maternal exposure to rituximab

(2010) E. F. Chakravarty et al.   BLOOD

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

(2010) David B Clifford et al.   LANCET NEUROLOGY

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial

(2010) R. T. Naismith et al.   NEUROLOGY

Inclusion of Rituximab in Treatment Protocols for Non-Hodgkin's Lymphomas and Risk for Progressive Multifocal Leukoencephalopathy

(2010) M. Tuccori et al.   ONCOLOGIST

Rituximab-Associated Infections

(2010) Juan C. Gea-Banacloche   SEMINARS IN HEMATOLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Regulatory T Cells Are Reduced During Anti-CD25 Antibody Treatment of Multiple Sclerosis

(2009) Unsong Oh et al.   ARCHIVES OF NEUROLOGY

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

(2009) K. R. Carson et al.   BLOOD

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model

(2009) Yanping Hu et al.   IMMUNOLOGY

B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis

(2009) Sara A. J. Thompson et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Melanoma complicating treatment with Natalizumab (Tysabri) for multiple sclerosis

(2009) Azza Ismail et al.   JOURNAL OF NEUROLOGY

Daclizumab in treatment of multiple sclerosis patients

(2009) EN Ali et al.   Multiple Sclerosis Journal

GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study

(2009) A. D. Goodman et al.   NEUROLOGY

Monoclonal antibodies in MS: Mechanisms of action

(2009) B. Bielekova et al.   NEUROLOGY

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

(2008) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab

(2008) Maria del Pilar Martin   ARCHIVES OF NEUROLOGY

Getting specific: monoclonal antibodies in multiple sclerosis

(2008) Andreas Lutterotti et al.   LANCET NEUROLOGY

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis

(2008) M. Krumbholz et al.   NEUROLOGY

The B Cell — Old Player, New Position on the Team

(2008) Henry F. McFarland   NEW ENGLAND JOURNAL OF MEDICINE

Anti–Glomerular Basement Membrane Disease after Alemtuzumab

(2008) Menna R. Clatworthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protein therapeutics: a summary and pharmacological classification

(2007) Benjamin Leader et al.   NATURE REVIEWS DRUG DISCOVERY